Lucentis and Blepharitis - a phase IV clinical study of FDA data

Summary:

Blepharitis is reported as a side effect among people who take Lucentis (ranibizumab), especially for people who are female, 60+ old, have been taking the drug for 2 - 5 years also take Avastin, and have Age-related macular degeneration.

The phase IV clinical study analyzes which people have Blepharitis when taking Lucentis. It is created by eHealthMe based on reports of 25,577 people who have side effects when taking Lucentis from the FDA, and is updated regularly.

What is Lucentis?

Lucentis has active ingredients of ranibizumab. It is often used in macular degeneration. eHealthMe is studying from 25,647 Lucentis users. Check the latest studies of Lucentis.

What is Blepharitis?

Blepharitis (chronic inflammation of the eyelid) is found to be associated with 514 drugs and 689 conditions by eHealthMe. Check the latest studies of Blepharitis.

On Apr, 11, 2026

25,577 people reported to have side effects when taking Lucentis.
Among them, 43 people (0.17%) have Blepharitis.

Among these 43 people:

How long have people been on Lucentis when they have Blepharitis? *

What is the gender of people who have Blepharitis when taking Lucentis? *

female: 65 %
male: 35 %

What is the age of people who have Blepharitis when taking Lucentis? *

What are other drugs people take besides Lucentis? *

What are other side effects people have besides Blepharitis? *

Visual Acuity Reduced (reduced clearness of vision): 16 people, 37.21%
Detachment Of Retinal Pigment Epithelium: 12 people, 27.91%
Metamorphopsia (a type of distorted vision in which a grid of straight lines appears wavy and parts of the grid may appear blank): 11 people, 25.58%
Choroidal Neovascularisation (creation of new blood vessels in vascular layer of eye): 11 people, 25.58%
Vitreous Floaters (spots before the eyes): 9 people, 20.93%
Dry Eyes (lack of adequate tears): 9 people, 20.93%
Macular Fibrosis (a thin sheet of scar tissue forms on top of the macula, in response to damage or injury): 8 people, 18.60%
Macular Oedema (fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken): 8 people, 18.60%
Retinal Degeneration (death of the cells of the retina): 7 people, 16.28%
Glaucoma (increased fluid pressure in the eye with vision loss): 7 people, 16.28%

What are the existing conditions these people have? *

Age-Related Macular Degeneration: 21 people, 48.84%
Retinal Oedema (swelling of retina): 4 people, 9.30%
Macular Fibrosis (a thin sheet of scar tissue forms on top of the macula, in response to damage or injury): 3 people, 6.98%
Diabetic Retinopathy (damage to the retina caused by complications of diabetes): 3 people, 6.98%
Cystoid Macular Oedema (fluid accumulation after cataract surgery): 3 people, 6.98%
Venous Occlusion (the blocking of venous return): 2 people, 4.65%
Diabetic Retinal Oedema (excessive build-up of fluid in the retina due to diabetes): 2 people, 4.65%
Wheezing (a high-pitched whistling sound made while you breath): 1 person, 2.33%
Vitreous Adhesions: 1 person, 2.33%
Retinitis Histoplasma (fungal infection of retina): 1 person, 2.33%

* Approximation only. Some reports may have incomplete information.

Do you take Lucentis and have Blepharitis?

- Check whether Blepharitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lucentis:

Lucentis (25,647 reports)

Blepharitis treatments and more:

Blepharitis (5,399 reports)

Browse all side effects of Lucentis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Blepharitis:

Blepharitis (514 drugs)

Browse all the conditions that are associated with Blepharitis:

Blepharitis (689 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ranibizumab (the active ingredients of Lucentis) and Lucentis (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.